BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1774436)

  • 1. HLA-B8,DR3 T cell impairment is completely restored by in vitro treatment with interleukin-2.
    Candore G; Colucci AT; Modica MA; Caruso C
    Immunopharmacol Immunotoxicol; 1991; 13(4):551-61. PubMed ID: 1774436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of T lymphocyte activation in HLA-B8, DR3 positive individuals.
    Modica MA; Zambito AM; Candore G; Caruso C
    Immunobiology; 1990 Nov; 181(4-5):257-66. PubMed ID: 2129202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro cytokine production by HLA-B8,DR3 positive subjects.
    Candore G; Cigna D; Gervasi F; Colucci AT; Modica MA; Caruso C
    Autoimmunity; 1994; 18(2):121-32. PubMed ID: 7742473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual susceptibility to hexavalent chromium of workers of shoe, hide, and leather industries. Immunological pattern of HLA-B8, DR3-positive subjects.
    Mignini F; Streccioni V; Baldo M; Vitali M; Indraccolo U; Bernacchia G; Cocchioni M
    Prev Med; 2004 Oct; 39(4):767-75. PubMed ID: 15351544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective expression of CD95 (FAS/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8, DR3-positive individuals.
    Stassi G; Todaro M; De Maria R; Candore G; Cigna D; Caruso C; Galluzzo A; Giordano C
    Hum Immunol; 1997 Jun; 55(1):39-45. PubMed ID: 9328788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble interleukin-2 receptor secretion defect in vitro in HLA-B8, DR3 positive subjects.
    Modica MA; di Lorenzo G; Galluzzo A; Giordano C; Portelli MR; Candore G; Caruso C
    Autoimmunity; 1990; 7(2-3):87-96. PubMed ID: 2104185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of a lymphocyte abnormality associated with HLA-B8/DR3 in clinically healthy individuals.
    Hashimoto S; McCombs CC; Michalski JP
    Clin Exp Immunol; 1989 Jun; 76(3):317-23. PubMed ID: 2787712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of a lymphocyte abnormality associated with HLA-B8/DR3: role of interleukin-1.
    Hashimoto S; Michalski JP; Berman MA; McCombs C
    Clin Exp Immunol; 1990 Feb; 79(2):227-32. PubMed ID: 2311300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell activation in HLA-B8, DR3-positive individuals. Early antigen expression defect in vitro.
    Candore G; Cigna D; Todaro M; De Maria R; Stassi G; Giordano C; Caruso C
    Hum Immunol; 1995 Apr; 42(4):289-94. PubMed ID: 7558912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypothesis: interleukin-5 production impairment can be a key point in the pathogenesis of the MHC-linked selective IgA deficiency.
    Lio D; D'Anna C; Leone F; Currò MF; Candore G; Caruso C
    Autoimmunity; 1998; 27(3):185-8. PubMed ID: 9609136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood antiphospholipid antibody levels are influenced by age, sex and HLA-B8,DR3 phenotype.
    Colucci AT; Di Lorenzo G; Ingrassia A; Crescimanno G; Modica MA; Candore G; Caruso C
    Exp Clin Immunogenet; 1992; 9(2):72-9. PubMed ID: 1489552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of cytokine patterns in subjects bearing the HLA-B8,DR3 phenotype: implications for autoimmunity.
    Lio D; Candore G; Romano GC; D'Anna C; Gervasi F; Di Lorenzo G; Modica MA; Potestio M; Caruso C
    Cytokines Cell Mol Ther; 1997 Dec; 3(4):217-24. PubMed ID: 9740350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased interleukin-2 receptor affinity in normal HLA A1 B8 DR3 subjects.
    Pomier G; Vindimian M; Healy JC; Le Petit JC
    J Immunogenet; 1990 Dec; 17(6):371-7. PubMed ID: 2096181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [T-helper (CD4+) cytopenia and HLA-A1, -B8, -C27, -DR3].
    Kuntz BM; Sobieraj B; Brüster HT
    Beitr Infusionsther Transfusionsmed; 1994; 32():310-3. PubMed ID: 9480115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood IgA, IgM and IgE levels are influenced by sex and HLA phenotype.
    Modica MA; Freddi S; Caruso C
    Exp Clin Immunogenet; 1989; 6(4):251-7. PubMed ID: 2488685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro impairment of interleukin-5 production in HLA-B8, DR3-positive individuals implications for immunoglobulin A synthesis dysfunction.
    Lio D; D'Anna C; Gervasi F; Cigna D; Modica MA; Candore G; Caruso C
    Hum Immunol; 1995 Nov; 44(3):170-4. PubMed ID: 8666553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer and lymphokine-activated killer activity in HLA-B8,DR3-positive subjects.
    Caruso C; Candore G; Colucci AT; Cigna D; Modica MA; Tantillo G; Salerno A
    Hum Immunol; 1993 Nov; 38(3):226-30. PubMed ID: 8106282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-B8,DR3 phenotype and lymphocyte responses to phytohaemagglutinin.
    Modica MA; Cammarata G; Caruso C
    J Immunogenet; 1990; 17(1-2):101-7. PubMed ID: 2212697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequencies of HLA-DR3, -DR4, -B8 and -Bw62 in diabetic children diagnosed between 1960 and 1990.
    Mäenpää A; Koskimies S; Scheinin T; Schlenzka A; Akerblom HK; Mäenpää J; Reunanen A; Kontiainen S
    Diabetes Res; 1991 Apr; 16(4):159-63. PubMed ID: 1802481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-B8,DR3 haplotype affects lymphocyte blood levels.
    Caruso C; Bongiardina C; Candore G; Cigna D; Romano GC; Colucci AT; Di Lorenzo G; Gervasi F; Manno M; Potestio M; Tantillo G
    Immunol Invest; 1997 Apr; 26(3):333-40. PubMed ID: 9129986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.